Pre-filled Syringe
IBSA laboratories have developed HYALUXELLE®. indicated for adult women. HYALUXELLE® intervenes in the physiological process of the reduction of skin hydration, alteration of the elastic fibres and collagen of the dermis with loss of turgor and skin tone, for example in cases of excessive dehydration, weight loss and aging, with relative loss of endogenous HA.
The pre-filled syringe technology simplifies the administration of the product, perfectly sterile, reducing the risk of errors, consequently improving safety.
HYALUXELLE® is composed of a buffered saline solution of high molecular weight (H-HA) and low molecular weight (L-HA) hyaluronic acid. The high- and low-molecular-weight HA used in the device is obtained by biofermentation and has not undergone chemical modification processes; this results in excellent tolerability of the product.
Want to know more about the technology?
Contact usWant to know who is IBSA?
DISCOVER MOREDo you want to know more?
Fill the form to contact us

IBSA Business Development
Since 2018, there has been a new Department in IBSA fully dedicated to Business Development, Licensing activities and CDMO projects. Licensing The Business Development Dept. is constantly looking for partners and international distributors for licensing agreements in countries where IBSA does not operate directly with its branches. IBSA is focused on strategic collaborations to achieve a common goal while sharing responsibilities, resources, risks and rewards. Close ties with local distributors are crucial for IBSA to grow at an international level. The Business Development Dept. also evaluates licensing-in opportunities for the expansion of product portfolio.